moxifloxacin has been researched along with acarbose in 4 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (acarbose) | Trials (acarbose) | Recent Studies (post-2010) (acarbose) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 131 | 0 | 122 |
| 3,157 | 552 | 1,690 | 118 | 0 | 86 |
| Protein | Taxonomy | moxifloxacin (IC50) | acarbose (IC50) |
|---|---|---|---|
| Alpha-amylase | Acarus siro | 3.8 | |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | 2 | |
| Pancreatic alpha-amylase | Sus scrofa (pig) | 4.3108 | |
| Alpha-amylase 1A | Homo sapiens (human) | 0.996 | |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | 5 | |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | 2 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 2 | |
| Oligo-1,6-glucosidase IMA1 | Saccharomyces cerevisiae S288C | 9.37 | |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | 2 | |
| Chain A, Cyclomaltodextrin glucanotransferase | Bacillus sp. 1011 | 5600 | |
| Sucrase-isomaltase, intestinal | Rattus norvegicus (Norway rat) | 1.97 | |
| Lysosomal alpha-glucosidase | Rattus norvegicus (Norway rat) | 1.3892 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
1 review(s) available for moxifloxacin and acarbose
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for moxifloxacin and acarbose
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |